Analyst Expectations for Insulet’s Future
Over the past 3 months, 4 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are…
Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $325
Morgan Stanley analyst Cecilia Furlong maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $320 to $325.
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Insulet Acquires Assets Related To Bigfoot’s Pump-based Automated Insulin Delivery Technologies For $25M, Including Certain Bigfoot Patents Related To Pumps That May Be Used For Automated Insulin Delivery Therapy
The transaction further strengthens Insulet's intellectual property (IP) portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity® Diabetes Management System to more people in need of
Wolfe Research Initiates Coverage On Insulet with Peer Perform Rating
Wolfe Research analyst Mike Polark initiates coverage on Insulet (NASDAQ:PODD) with a Peer Perform rating.
Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $320
Morgan Stanley analyst Cecilia Furlong maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $300 to $320.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Insulet Issues Medical Device Correction For Omnipod 5 Controller Due To Faulty Charging
Insulet Corporation (NASDAQ:PODD) announced a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System because of an issue with…
